focus -WSS

focus

author：Wikipedia 2025-09-29 22:36:25 - browse：6187

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Thursday released a new accounting of artificial intelligence tools cleared for use in health care, adding scores of new products designed to reshape care in several areas of medicine.

The update included 171 new products that use artificial intelligence and machine learning, including 155 authorized since August of 2022. The agency’s data indicate that, after a lull during the Covid-19 pandemic, the number of authorized devices in 2023 is expected to increase by more than 30% over the prior year.

The list of AI devices was first published after a STAT investigation reported that the FDA had failed to keep the public informed on its regulation of AI devices, or crucial details on the tests undertaken to prove their safety and effectiveness. The summary documents that describe new AI devices often fail to break out the demographics of the patients they were tested on, or where the testing took place, which makes it difficult for clinicians and patients to understand their potential biases and weaknesses.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： FDA approves RSV monoclonal antibody for infants, toddlers

WSS

Hospitals are piloting generative AI tools as regulators play catch

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

In early work, researchers turn to CRISPR to treat Alzheimer's

Why hospitals are withdrawing from US News rankings

Sanofi seeks simpler, safer CRISPR sickle cell cure

A public scorecard can help hold safety

focus

focus

focus

Anesthesiologist group: stop taking Ozempic before surgery

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Virginia high school admissions case could be legal follow

WATCH: Why do our ears pop?

Psychedelics group wrestles with new pharma identity

Ukraine seeks to reclaim its role as a hub for clinical trials

In Memoriam: Notable people who died in 2023

Cosmetics set for new safety regulation. Why the industry is on board

In age of alternative facts, a scholarly course on calling out crap

Sanofi seeks simpler, safer CRISPR sickle cell cure

entertainment

AI can’t replace a physician’s gut feeling

How dance can help nurses traumatized by Covid

Sanofi seeks simpler, safer CRISPR sickle cell cure

In early work, researchers turn to CRISPR to treat Alzheimer's

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Wikipedia

entertainment

knowledge

Wikipedia